Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
radioiodine-labeled human serum albumin
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Radioiodine-labeled human serum albumin is a **diagnostic radiopharmaceutical** comprised of **human serum albumin** covalently labeled with a radioactive iodine isotope (most commonly iodine-125 or iodine-131)[1][2][6][7]. After intravenous injection, it remains primarily within the vascular compartment, enabling accurate measurement of blood volume, plasma volume, vascular permeability, and assessment of protein-losing gastroenteropathy through quantitative detection of the radiolabel using gamma cameras or other nuclear medicine techniques[1][5][6][7]. The primary mechanism involves tracking the distribution and clearance of albumin in the body using the radioisotope signal. The drug's developer and manufacturer are most notably **GE Healthcare** for Jeanatope (I-125 albumin); other formulations are produced by various diagnostic radiopharmaceutical manufacturers[5]. The drug is not for treatment but serves as a diagnostic agent in nuclear medicine.
- Brand names
- JeanatopeVolumexMegatope
- Other names
- iodinated I-125 albuminiodinated I-131 albuminradioiodinated serum albuminradio-iodinated human serum albuminradioiodine-labeled human albumin
Beyond the preview
Go deeper on radioiodine-labeled human serum albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on radioiodine-labeled human serum albumin.